TargetMol

Tasisulam

Product Code:
 
TAR-T6191
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T6191-5mg5mg£99.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6191-1mL1 mL * 10 mM (in DMSO)£114.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6191-10mg10mg£115.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6191-25mg25mg£172.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6191-50mg50mg£243.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6191-100mg100mg£329.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6191-200mg200mg£458.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T6191-500mg500mg£704.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Tasisulam is an apoptosis inducer and an antitumor agent via the intrinsic pathway.
CAS:
519055-62-0
Formula:
C11H6BrCl2NO3S2
Molecular Weight:
415.1
Pathway:
Apoptosis; Proteases/Proteasome
Purity:
0.9997
SMILES:
Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1
Target:
Apoptosis; Caspase

References

Haritunians T, et al. Oncol Rep. 2008, 20(5), 1237-1242. Meier T, et al. Mol Cancer Ther. 2011, 10(11), 2168-2178.